Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

Дата публикации: 02-07-2026 21:20:06

For adults with type 2 diabetes mellitus (T2DM), bofanglutide, a glucagon-like peptide-1 receptor agonist, is associated with more meaningful reductions in hemoglobin A1C (HbA1c) levels than semaglutide, according to a study published online June 30 in the Annals of Internal Medicine.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds	0	10.14	13-10-2026
2	New weight loss pill beats oral Ozempic in major trial	0	9.35	07-07-2026
3	GLP-1 Medications May Improve Health in People With PAD and Diabetes	0	9.88	18-08-2026
4	GLP-1 Agonists May Help People With Diabetes and Long COVID	0	10.36	09-07-2026
5	Weight‑loss jabs may create a new kind of yo‑yo dieting	0	7	10-07-2026
6	Comparative effectiveness of metabolic bariatric surgery versus incretin-based and medical therapies for weight loss and glycemic outcomes: a systematic review and meta-analysis [version 1; peer review: awaiting peer review]	0	8.4	13-07-2026
7	Stanford researchers say your body already makes this Ozempic alternative	0	7	15-06-2026
8	Ученые выявили новый побочный эффект приема "Оземпика"	0	7	30-06-2026
9	Most obesity drugs do not improve quality of life or heart health, analysis indicates	-2	7	08-07-2026
10	New treatment helps achieve a healthier BMI in people with weight dysregulation after brain tumors	5	7	09-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 5. Информативность: 7. Источник: medicalxpress.com.